Infliximab
Cold Chain RequiredFDA Approved
Contents
Description
Infliximab is a TNF blocker used to reduce inflammation in autoimmune conditions. It is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), preventing it from binding to its receptors.
Indications & Therapeutic Use
Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis
Linked Diseases:
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Infliximab — GNH India
35 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
AVSOLA
100 MGpowder for solutionCANADA
Flixabi
EU
Inflectra
EU
IXIFI
100 MGpowder for solutionCANADA
REMDANTRY
100 MGpowder for solutionKOREA, REPUBLIC OF
Remicade
EU
Remsima
EU
REMSIMA SC
120 MGkitKOREA, REPUBLIC OF
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Infliximab
| Generic Name | Infliximab |
| Brands | 1 brand available |
| Active Ingredient | Infliximab |
| Drug Class | Rheumatoid Arthritis |
| Manufacturer | Janssen Biotech |
| Dosage Forms | Intravenous infusion |
| Medical Code | L04AB02 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00026270 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes